Collectively, these findings indicate that PD-1 blocking is able in inducing ILC2 expansion and cytokine secretion but the clinical benefit would rely on ILC2 capability to effectively migrate within the tumor lesions in order to exert their anti-melanoma effects. Here, PDCD1 is linked to neoplasm.